DTCFF - Defence Therapeutics receives U.S. patent for vaccine platform technology

Defence Therapeutics (OTCPK:DTCFF) said the United States Patent and Trademark Office (USPTO) had granted a patent number to its vaccine platform technology for the treatment and prevention of a wide range of cancers and infectious diseases, including COVID-19. The patent number '717 will provide protection for Defence's vaccine platform that can be used virtually in any cell-based or protein subunit vaccine.  The company said the patent was allowed by the USPTO within an expedient three months without any substantive amendments. The vaccine platform uses components of Defence's Accum  technology.

For further details see:

Defence Therapeutics receives U.S. patent for vaccine platform technology